Pegloticase

Pegloticase is an FDA-approved medication used to treat adults with gout. It is a pegylated form of uricase, an enzyme that breaks down uric acid. Pegloticase works by lowering uric acid levels in the blood, which can reduce the pain and inflammation caused by gout. It is usually given as an intravenous infusion once every two weeks. Common side effects include nausea, injection site reactions, and shortness of breath.

Pegloticase, also sold under the brand name Krystalose, is a medication used to treat chronic gout in adults. Here's a breakdown of its key features:

What it's for:

• Pegloticase targets chronic gout, a condition characterized by recurrent gout attacks caused by excess uric acid in the body. Uric acid forms crystals that deposit in joints, leading to inflammation and intense pain.

How it Works:

• Unlike other gout medications that focus on managing gout attacks, pegloticase works differently. It's a recombinant enzyme that breaks down uric acid into a soluble form that the body can eliminate through urine. By reducing uric acid levels, pegloticase helps prevent future gout attacks.

Important Points:

• Dosage and Administration: Pegloticase is given as an intravenous (IV) infusion into a vein over approximately 30 minutes. The initial dose and frequency of infusions depend on individual factors, but typically follow a schedule established by your doctor.
• Special Considerations: Pegloticase is not for everyone. People with certain medical conditions, like uncontrolled tumor lysis syndrome or significant kidney problems, may not be suitable candidates. Additionally, it can cause serious allergic reactions, so close monitoring during and after infusions is essential.
• Effectiveness: Pegloticase can be very effective in reducing uric acid levels and preventing gout attacks. However, it's a long-term medication requiring consistent therapy to maintain its benefits.